Search Results for ""

Patient navigation has the potential to improve patient satisfaction, reduce health disparities, and ultimately optimize cancer outcomes. However, navigation services are often funded externally through grants or considered unreimbursed administrative costs because of lack of reimbursement. In January 2024, the Centers for Medicare and Medicaid Services (CMS) established its first coding and payment for principal illness navigation (PIN) services. CMS said that funding the services would improve health equity in patients with serious, high-risk conditions such as cancer.

Dance/movement therapy (DMT) is an integrative symptom management modality that uses the elements of dance and movement along with other body-focused activities, including guided imagery, mindfulness, breath awareness, and therapeutic play to support self-expression and promote well-being. Defined by the American Dance Therapy Association as “the psychotherapeutic use of movement to promote emotional, social, cognitive and physical integration of the individual,” DMT has been used in pediatric cancer settings. However, data on its delivery and outcomes are limited.

A few years ago, ONS member Amy Gundelach, RN, MSN, AG-CNS-BC, OCN®, survivorship program coordinator at the University of New Mexico (UNM) Comprehensive Cancer Center in Albuquerque, was managing two male patients—a 25-year-old and a 30-year-old—who were seeking a survivorship support group of young adult peers and a survivorship therapist for young adults. She discovered that her institution didn’t have any materials tailored specifically tailored for young adult cancer survivors’ needs, compared to their older counterparts.

Innovation—a proactive effort to create or build on ideas—is something that oncology nurses and advanced practice providers (APPs) do every day. This month’s 49th Annual ONS Congress® reminds us to “ignite the extraordinary” and recognize how we can use our strengths to blaze new trails for oncology and health care. Step by step, we all have opportunities to innovate in oncology nursing through evidence-based practice, quality improvement, the development of new products and technology, and research.

Washington, DC, is a city full of inspiration and opportunities to ignite the extraordinary. That is why I am excited to share tips and tricks of how to explore this vibrant and historic city while attending the 2024 ONS Congress. 

With an ever-growing number of apheresis procedures and a rising chronic apheresis patient population, there is a need for long-term vascular access options. BD is a global leader in ports and we have listened to the challenges and needs of the apheresis community.

ONS Congress is right around the corner, and I am excited to share how you can stay organized and plan how you want to spend your days during the five-day conference.

We are thrilled to gather once again as a group of nurses sharing our passion for providing the best cancer care possible to our patients! We hope you will find your time in Washington, DC, not only educational but invigorating. We have opportunities available for you to refresh and recharge so you can continue to have an overflowing cup to pour from. 

After an open-label, multicenter, single-arm trial demonstrated a 56% objective response rate, with 43% achieving complete responses, and an estimated 18.4-month median duration of response, the U.S. Food and Drug Administration granted glofitamab-gxbm (Columvi™) accelerated approval in June 2023. 

Margetuximab-cmkb (Margenza®) received U.S. Food and Drug Administration approval in December 2020 for previously treated adults with metastatic HER2-positive breast cancer after clinical trials demonstrated increased progression-free and overall survival.